Our findings suggest that targeting inflammation and oxidative stress through anti-inflammatory and antioxidant therapies, in addition to the use of SGLT2-inhibitors such as empagliflozin, may provide potential therapeutic strategies for managing patients with concurrent DM and AS. This evidence concerns the gene SLC5A2 and aortic valve stenosis.